Zevra Therapeutics, Inc.
ZVRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeZevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The $736.4M market capitalization puts ZVRA squarely in small-cap range for its industry. The company develops its products through Ligand Activated Technology platform.
Market Cap
$736.4M
Beta
0.95
P/E (TTM)
13.48
P/E (Fwd)
11.52
EPS (TTM)
$0.92
EPS (Fwd)
$1.08
ROE
34.8%
ROA
8.7%
Cash
$221.6M
Total Debt
$1.5M
Free CF
$48.4M
52W Change
50.5%
Annual Financials
Cash vs Debt
Where ZVRA stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, ZVRA finished 11.77% above its 150-day moving average ($10.62) and 16.95% above its 200-day moving average ($10.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZVRA overbought or oversold?
At the August 24, 2026 close, ZVRA's RSI(14) was 73.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $221.6M in cash comfortably exceeding the $1.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $48.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 34.8% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $10.2M (2022) to $106.5M (2025), reflecting a 948% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Zevra Therapeutics, Inc.'s trajectory.